Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research report report published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Stock Up 2.9 %

NASDAQ:APTO opened at $0.40 on Friday. The firm’s fifty day simple moving average is $0.40 and its 200-day simple moving average is $0.74. The stock has a market cap of $7.24 million, a PE ratio of -0.06 and a beta of 1.26. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.32.

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading